Literature DB >> 35585292

Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy.

Boddapati Kalyani Bhardwaj1, Sanu Thankachan1, Priyanila Magesh1, Thejaswini Venkatesh2, Rie Tsutsumi3, Padmanaban S Suresh4.   

Abstract

Ovarian cancer is one of the leading causes of cancer-related deaths among women. The drawbacks of conventional therapeutic strategies encourage researchers to look for alternative strategies, including nanotechnology. Nanotechnology is one of the upcoming domains of science that is rechanneled towards targeted cancer therapy and diagnosis. Nanocarriers such as dendrimers, liposomes, polymer micelles, and polymer nanoparticles present distinct surface characteristics in morphology, surface chemistry, and mode of action that help differentiate normal and malignant cells, which paves the way for target-specific drug delivery. Similarly, nanoparticles have been strategically utilized as efficacious vehicles to deliver drugs that alter the epigenetic modifications in epigenetic therapy. Some studies suggest that the use of specialized target-modified nanoparticles in siRNA-based nanotherapy prevents internalization and improves the antitumor activity of siRNA by ensuring unrestrained entry of siRNA into the tumor vasculature and efficient intracellular delivery of siRNA. Moreover, research findings highlight the significance of utilizing nanoparticles as depots for photosensitive drugs in photodynamic therapy. The applicability of nanoparticles is further extended to medical imaging. They serve as contrast agents in combination with conventional imaging modalities such as MRI, CT, and fluorescence-based imaging to produce vivid and enhanced images of tumors. Therefore, this review aims to explore and delve deeper into the advent of various nanotechnology-based therapeutic and imaging techniques that provide non-invasive and effective means to tackle ovarian cancers.
© 2022. Society for Reproductive Investigation.

Entities:  

Keywords:  Dendrimers; Liposomes; Ovarian cancer; Polymer nanoparticles

Year:  2022        PMID: 35585292     DOI: 10.1007/s43032-022-00968-1

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  58 in total

1.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins.

Authors:  T V Byzova; C K Goldman; N Pampori; K A Thomas; A Bett; S J Shattil; E F Plow
Journal:  Mol Cell       Date:  2000-10       Impact factor: 17.970

Review 2.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

Authors:  H Maeda
Journal:  Adv Enzyme Regul       Date:  2001

3.  Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-04-06       Impact factor: 15.470

Review 4.  A reevaluation of integrins as regulators of angiogenesis.

Authors:  Richard O Hynes
Journal:  Nat Med       Date:  2002-09       Impact factor: 53.440

Review 5.  Challenges for chemotherapy in ovarian cancer.

Authors:  R F Ozols
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

6.  Folate-PEG-superparamagnetic iron oxide nanoparticles for lung cancer imaging.

Authors:  Mi-Kyong Yoo; In-Kyu Park; Hwang-Tae Lim; Sang-Joon Lee; Hu-Lin Jiang; You-Kyoung Kim; Yun-Jaie Choi; Myung-Haing Cho; Chong-Su Cho
Journal:  Acta Biomater       Date:  2012-04-24       Impact factor: 8.947

7.  Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.

Authors:  S S Dharap; Y Wang; P Chandna; J J Khandare; B Qiu; S Gunaseelan; P J Sinko; S Stein; A Farmanfarmaian; T Minko
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-25       Impact factor: 11.205

8.  Design of folic acid-conjugated nanoparticles for drug targeting.

Authors:  B Stella; S Arpicco; M T Peracchia; D Desmaële; J Hoebeke; M Renoir; J D'Angelo; L Cattel; P Couvreur
Journal:  J Pharm Sci       Date:  2000-11       Impact factor: 3.534

Review 9.  The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.

Authors:  Frank C Passero; Dimitra Grapsa; Kostas N Syrigos; Muhammad Wasif Saif
Journal:  Expert Rev Anticancer Ther       Date:  2016-06-03       Impact factor: 4.512

Review 10.  Onivyde for the therapy of multiple solid tumors.

Authors:  Haijun Zhang
Journal:  Onco Targets Ther       Date:  2016-05-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.